Olmedo CV, Del Ángel CR, Rosas HL, Ramiro HM

Language: Spanish
References: 8
Page: 73-79
PDF size: 89.50 Kb.

ABSTRACT

Objective: To investigate the efficacy of pioglitazone to diminish the hemoglobin glycated in patients with diabetes mellitus type 2 (DM 2). Material and methods: Clinical controlled not randomized essay she I tired in a diabetes type 2 with HbA1c > 9 after 6 month with pharmacological (maximum doses oral glucose-lowering agents or use of insulin at 1 U/kg) treatment, dietary (25 kcal/kg) and exercise (daily walk for 30 minutes). The cohort was continued for 24 weeks measurement of blood glucose, HbA1c, hepatic test and lipids levels each 8 weeks. Since week 0 we started treatment with pioglitazone 15 mg per day and at 8 weeks later the dosage of pioglitazone was changed according with the HbA1c results. Results: Cohort of 37 females and 12 males with ages between to and 80 years old average basal. HbA1c levels of 10.5% and average glycemic of 225 mg/dL. At 8 week 37 patients (75.5%) increased doses of pioglitazone 30 mg, the rest of patients continued with 15 mg of pioglitazone; 16 week doses of pioglitazone was 5 patients with 15 mg (10.2%), 21 patients with 30 mg (42.9%) and 23 patients with 45 mg (46.9%). At the end of the study the levels of glycemia, HbA1c total cholesterol and triglyceride had as an statistic significantly reduction with a p < 0.001. Conclusions: At significant reduction of levels of HbA1c is possible using pioglitazone with dietary and drug therapy; but the levels cant be less tab 7% of HbA1c, we require to increase the observational period to determinate if we can reduce HbA1c to optimal levels.

REFERENCES

1. Kipnes MS, Krosnick A, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 1111: 10-17.

2. Kanelko T, Baba S, Toyota T et al. Dose Finding study of AD-4833 in NIDDM patients on treatment with a sulfonylurea drug. The Japanese J Clin and Experimental Medicine 1997; 74(5): 1278-1306.

3. Einhom D, Rendell M, Rosenzweig J et al. Pioglitazone Hydrochloride in Combination with metformin in the treatment of type 2 diabetes mellitus: a Randomized, placebo-controlled study. Clinical Therapeutics 2000; 22(12): 1395-1409.

4. Egan J, Rubin C, Maticeni A. Pioglitazone 027 study Group. Combination Therapy with pioglitazone and metformin in patients with type 2 diabetes. Diabetes 1999; 48(Suppl 1): A117.

5. Rubin C, Egan J, Schneider R. Pioglitazone 014 Study Group. Combination Therapy with pioglitazone and insulin in patients with type 2 diabetes. Diabetes 1999; 48 (Suppl 1): A110.

6. Ikeda H, Taketomi S, Sugiyama Y et al. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforsch ung Drugs Res 1990; 40(2 pt, 1): 156-162.

7. Sohda T, Momose Y, Meguro K et al. Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzil]2,4-tiazolidinediones. Arneimittelforschung Drug Res 1990; 40(1): 37-42.

8. Olmedo-Canchola V. Factores que influyen en la falta de adherencia al tratamiento dietético en los enfermos con DM2. Tesis de maestría. Facultad de Medicina UNAM 2000.